Category: 2023 Watch List

Most Popular

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia

The Kahner Global Cannabis & Psychedelics Investment Summit.

Kahner Global’s 8th annual Cannabis & Psychedelics Investment Summit  When:...

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE